NASDAQ:XENE
Xenon Pharmaceuticals Inc. Stock News
$40.31
-1.32 (-3.17%)
At Close: Apr 18, 2024
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
08:30am, Wednesday, 10'th Apr 2024
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present a
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
04:01pm, Thursday, 04'th Apr 2024
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present a
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
09:36am, Friday, 01'st Mar 2024
Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
10:08pm, Wednesday, 21'st Feb 2024
Now that the FED is looking to lower interest rates this year, cheaper money and more accessible financing will let investors venture into riskier places in the economy and the stock market. While not
Here's Why You Should Add Xenon (XENE) to Your Portfolio Now
09:41am, Tuesday, 23'rd Jan 2024
Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.
Wall Street Analysts Think Xenon Pharmaceuticals (XENE) Could Surge 25.76%: Read This Before Placing a Bet
10:56am, Friday, 19'th Jan 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionab
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:30am, Wednesday, 03'rd Jan 2024
VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at
Rare Stock Picks In November 2023 - From 31 Discerning Analysts
03:00pm, Thursday, 07'th Dec 2023
Welcome to another installment of our monthly Rare Stock Picks series. Today we're highlighting November 2023 investment picks you may have missed. As you know, some Seeking Alpha analysts are more di
Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study
12:47pm, Tuesday, 28'th Nov 2023
Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.
Xenon Pharma depression drug fails to meet study goal but analysts see positives
12:05pm, Monday, 27'th Nov 2023
Xenon Pharma shares moved higher on Monday despite the Vancouver, British Columbia neurology-focused biopharmaceutical company reporting that its investigational therapeutic for major depressive disor
Xenon Pharmaceuticals' stock falls as depression treatment has mixed results in clinical trial
08:30am, Monday, 27'th Nov 2023
Shares of Xenon Pharmaceuticals Inc. XENE fell 1.6% premarket on Monday after the neurology-focused company released new data from a clinical trial of its lead asset, an experimental depression treatm
Canada's Xenon Pharma's depression drug fails to meet main goal in study
07:43am, Monday, 27'th Nov 2023
Canada's Xenon Pharmaceuticals said on Monday that its experimental drug to treat moderate to severe major depressive disorder (MDD) had failed to significantly reduce the severity of depressive episo
Xenon Pharmaceuticals: XEN1101 Remains A Gem Despite The Dip
04:55am, Sunday, 26'th Nov 2023
XEN1101 shows clinical promise in epilepsy and MDD, with Phase 3 trials critical for its broader efficacy evaluation. Financially, Xenon faces a stark YOY revenue drop and rising R&D costs but maintai
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
04:01pm, Wednesday, 01'st Nov 2023
VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter
Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
08:30am, Friday, 06'th Oct 2023
VANCOUVER, British Columbia, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at
